Kiniksa Pharmaceuticals, Ltd.

KNSA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$43,193$14,084$183,363-$157,924
Dep. & Amort.$1,695$2,341$2,402$2,355
Deferred Tax$8,132-$33,788-$185,495$11
Stock-Based Comp.$30,693$27,149$25,120$25,173
Change in WC$24,809$1,350-$22,575$689
Other Non-Cash$3,553$2,165$2,992$3,398
Operating Cash Flow$25,689$13,301$5,807-$126,298
Investing Activities
PP&E Inv.-$277-$130-$105-$415
Net Acquisitions$25$0$0$0
Inv. Purchases-$202,014-$204,933-$135,864-$157,250
Inv. Sales/Matur.$239,938$175,506$127,800$306,300
Other Inv. Act.$0$0$91-$20,000
Investing Cash Flow$37,672-$29,557-$8,078$128,635
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$3,417$0
Stock Repurch.-$4,984-$2,206$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$17,250$3,701-$901$5,885
Financing Cash Flow$12,266$1,495$2,516$5,885
Forex Effect$0$0$0$0
Net Chg. in Cash$75,627-$14,761$245$8,222
Supplemental Information
Beg. Cash$107,954$122,715$122,470$114,248
End Cash$183,581$107,954$122,715$122,470
Free Cash Flow$25,412$13,171$5,702-$146,713